<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318147</url>
  </required_header>
  <id_info>
    <org_study_id>NanchanguniversityII</org_study_id>
    <nct_id>NCT02318147</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC)</brief_title>
  <official_title>Fecal Microbiota Transplantation in SAP（Severe Acute Pancreatitis）Patients With Infectious Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Nanchang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infectious complications are responsible for most of deaths in acute pancreatitis.Intestinal
      barrier dysfunction and increased intestinal permeability was associated with bacterial
      translocation which is believed to prompted these infections.The purpose of this clinical
      trail is to observe the potential capability of FMT in reduce the bacterial translocation and
      alleviate infectious complications by the reconstruction of a gut functional state.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators aims to restore the intestinal bacteria homeostasis through FMT by retention
      enema with fresh bacteria,thus minimizing bacterial translocation and alleviating infectious
      complications. The investigators will further examine the effect of FMT on the incidence of
      infectious complications，duration of clinical course and mortality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The control of infectious complications</measure>
    <time_frame>From admission to discharge</time_frame>
    <description>The temperature recovered to normal for 3 days. The inflammatory cytokines decreased to the normal value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein（CRP）level</measure>
    <time_frame>1day before intervention，7days and 14days after intervention</time_frame>
    <description>C-reactive protein (CRP) is a inflammatory prognostic marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitionin（PCT）level</measure>
    <time_frame>1day before intervention，7days and 14days after intervention</time_frame>
    <description>Procalcitionin（PCT）level is a inflammatory prognostic marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive care time and hospital stay</measure>
    <time_frame>From admission to discharge</time_frame>
    <description>The time of stay in the intensive care unit and hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From admission to discharge</time_frame>
    <description>The incidence of death during the time frame</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Pancreatitis</condition>
  <condition>Fecal Microbiota Transplantation</condition>
  <condition>Bacterial Translocation</condition>
  <condition>Infectious Complications</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The traditional treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The traditional treatment of SAP according to the associated guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>FMT by retention enema with fresh bacteria from healthy donor</description>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <other_name>Fecal Microbiota Therapy</other_name>
    <other_name>Fecal Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The traditional treatment</intervention_name>
    <description>the traditional treatments according to associated guidelines</description>
    <arm_group_label>Fecal Microbiota Transplantation</arm_group_label>
    <arm_group_label>The traditional treatment</arm_group_label>
    <other_name>Conventional drugs according to the guideline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of severe acute pancreatitis from the First Affiliated Hospital of Nanchang
             University according to the Classification of acute pancreatitis-2012: revision of the
             Atlanta classification and definitions by international consensus

          2. Onset of pancreatitis more than 2 weeks

          3. Intestinal bacterium screening tips gut dysbacteriosis

          4. Patients with symptoms of infection, such as fever, abdominal pain or blood culture
             and pancreatic necrosis drainage culture positive patients.

        Exclusion Criteria:

          1. SAP complicated by Gastrointestinal bleeding or Intestinal fistula

          2. Pregnancy and lactation women

          3. Not signed the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nonghua Lv, MD</last_name>
    <role>Study Chair</role>
    <affiliation>the Frist Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yin Zhu, MD</last_name>
    <phone>13970841464</phone>
    <email>zhuyin27@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lingyu Luo, MD</last_name>
    <phone>15270855639</phone>
    <email>15270855639@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nonghua Lv, MD</last_name>
      <phone>13707086809</phone>
      <email>lunonghua@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Kunhe Zhang, MD</last_name>
      <phone>13007202818</phone>
      <email>393467260@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nonghua Lv, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Liang J, Sha SM, Wu KC. Role of the intestinal microbiota and fecal transplantation in inflammatory bowel diseases. J Dig Dis. 2014 Dec;15(12):641-6. doi: 10.1111/1751-2980.12211. Review.</citation>
    <PMID>25389085</PMID>
  </reference>
  <reference>
    <citation>Li Q, Wang C, Tang C, He Q, Zhao X, Li N, Li J. Therapeutic modulation and reestablishment of the intestinal microbiota with fecal microbiota transplantation resolves sepsis and diarrhea in a patient. Am J Gastroenterol. 2014 Nov;109(11):1832-4. doi: 10.1038/ajg.2014.299.</citation>
    <PMID>25373588</PMID>
  </reference>
  <reference>
    <citation>Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol. 2015 Mar;179(3):363-77. doi: 10.1111/cei.12474. Review.</citation>
    <PMID>25345825</PMID>
  </reference>
  <reference>
    <citation>Besselink MG, van Santvoort HC, Renooij W, de Smet MB, Boermeester MA, Fischer K, Timmerman HM, Ahmed Ali U, Cirkel GA, Bollen TL, van Ramshorst B, Schaapherder AF, Witteman BJ, Ploeg RJ, van Goor H, van Laarhoven CJ, Tan AC, Brink MA, van der Harst E, Wahab PJ, van Eijck CH, Dejong CH, van Erpecum KJ, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group. Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. Ann Surg. 2009 Nov;250(5):712-9. doi: 10.1097/SLA.0b013e3181bce5bd.</citation>
    <PMID>19801929</PMID>
  </reference>
  <reference>
    <citation>Gu WJ, Liu JC. Probiotics in patients with severe acute pancreatitis. Crit Care. 2014 Jul 3;18(4):446. doi: 10.1186/cc13968.</citation>
    <PMID>25043372</PMID>
  </reference>
  <reference>
    <citation>Cui LH, Wang XH, Peng LH, Yu L, Yang YS. [The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013 Apr;25(4):224-8. doi: 10.3760/cma.j.issn.2095-4352.2013.04.011. Chinese.</citation>
    <PMID>23660099</PMID>
  </reference>
  <reference>
    <citation>Tellado JM. Prevention of infection following severe acute pancreatitis. Curr Opin Crit Care. 2007 Aug;13(4):416-20. Review.</citation>
    <PMID>17599012</PMID>
  </reference>
  <reference>
    <citation>Hooijmans CR, de Vries RB, Rovers MM, Gooszen HG, Ritskes-Hoitinga M. The effects of probiotic supplementation on experimental acute pancreatitis: a systematic review and meta-analysis. PLoS One. 2012;7(11):e48811. doi: 10.1371/journal.pone.0048811. Epub 2012 Nov 13. Review.</citation>
    <PMID>23152810</PMID>
  </reference>
  <reference>
    <citation>Aroniadis OC, Brandt LJ. Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. Gastroenterol Hepatol (N Y). 2014 Apr;10(4):230-7.</citation>
    <PMID>24976806</PMID>
  </reference>
  <reference>
    <citation>Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, Young VB. Recovery of the gut microbiome following fecal microbiota transplantation. MBio. 2014 Jun 17;5(3):e00893-14. doi: 10.1128/mBio.00893-14.</citation>
    <PMID>24939885</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2014</study_first_submitted>
  <study_first_submitted_qc>December 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2014</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Nanchang University</investigator_affiliation>
    <investigator_full_name>Lingyu Luo</investigator_full_name>
    <investigator_title>Physician-in-charge</investigator_title>
  </responsible_party>
  <keyword>Severe acute pancreatitis</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Bacterial Translocation</keyword>
  <keyword>Infectious Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

